GLP-1 agonists

Merck joins obesity pill race with up to $2B Hansoh deal
BioSpace
Wed, 12/18/24 - 11:18 am
Merck
obesity
China
Hansoh
GLP-1 agonists
A new GLP-1 opportunity for pharma: Supporting patients’ emotional barriers to weight loss
Pharmaphorum
Wed, 12/18/24 - 11:14 am
patients
GLP-1 agonists
obesity
weight loss
Novo Nordisk
Eli Lilly
Four oral GLP-1R products in Phase III trials as race intensifies
Clinical Trials Arena
Tue, 12/3/24 - 11:17 am
Novo Nordisk
Eli Lilly
Jiangsu Hengrui
GLP-1R
GLP-1 agonists
clinical trials
Novo, Viking heat up MASH space with promising data at AASLD24
BioSpace
Wed, 11/20/24 - 11:40 am
Novo Nordisk
Viking Therapeutics
MASH
AASLD
GLP-1 agonists
semaglutide
VK2809
Drugmakers and pharmacists battle over who gets to make obesity drugs
NPR
Wed, 11/20/24 - 11:21 am
Novo Nordisk
Eli Lilly
obesity
weight loss
GLP-1 agonists
compounded drugs
Novo’s Wegovy Launched in China at a Fraction of US Price
BioSpace
Mon, 11/18/24 - 11:28 am
Novo Nordisk
Wegovy
Cina
weight loss
GLP-1 agonists
Hims & Hers launches GLP-1 tracker amid shortages
Beckers Hospital Review
Mon, 11/18/24 - 11:23 am
drug shortages
GLP-1 agonists
Hims & Hers Health
Survey Finds Most GLP-1 Users Discontinue Drug Before Reaching Goal Weight
Xtalks
Fri, 11/15/24 - 11:27 am
Omada Health
GLP-1 agonists
obesity
weight loss
Novo Nordisk
Eli Lilly
Ozempic
Zepbound
Mounjaro
Wegovy
States slow to cover GLP-1s for weight loss
Axios
Wed, 11/6/24 - 11:37 am
Medicaid
GLP-1 agonists
Novo Nordisk
Eli Lilly
Wegovy
Zepbound
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
BioPharma Dive
Wed, 10/23/24 - 11:40 am
FDA
GLP-1 agonists
drug shortages
compounding pharmacies
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
Pharma Voice
Mon, 10/21/24 - 09:37 am
FDA
GLP-1 agonists
Ozempic
Wegovy
Novo Nordisk
drug shortages
Eli Lilly
Zepbound
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Motley Fool
Thu, 10/17/24 - 09:24 am
Novartis
GLP-1 agonists
obesity
weight loss
Inside the GLP-1 'price war'
Beckers Hospital Review
Tue, 09/24/24 - 11:52 am
GLP-1 agonists
obesity
weight loss
Eli Lilly
Novo Nordisk
Ozempic
Wegovy
Zepbound
Mounjaro
drug pricing
Ambrosia lands $16m to ‘improve on existing GLP-1 drugs’
Longevity Technology
Wed, 08/21/24 - 11:26 am
Ambrosia Biosciences
funding
GLP-1 agonists
obesity
Pfizer
Array Biopharma
Novo Nordisk’s Ozempic Could Help Curb Cigarette Use in Diabetics: Study
BioSpace
Tue, 07/30/24 - 11:40 am
Novo Nordisk
Ozempic
smoking cessation
GLP-1 agonists
‘Not prudent’ for Novartis to join GLP-1 obesity race as late-runner, says CEO
Fierce Biotech
Thu, 07/18/24 - 11:13 pm
Novartis
Pharma CEOs
obesity
Vas Narasimhan
GLP-1 agonists
GLP-1 global obesity market to reach $111B by 2033, despite headwinds: GlobalData
BioSpace
Fri, 06/14/24 - 11:48 am
GLP-1 agonists
Novo Nordisk
Eli Lilly
obesity
weight loss
Novo attempts to parry Sanders' GLP-1 pricing complaints by calling out pharma middlemen
Fierce Pharma
Wed, 05/29/24 - 09:32 pm
Novo Nordisk
Senate
drug pricing
GLP-1 agonists
Bernie Sanders
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
Reuters
Wed, 05/1/24 - 09:33 am
Denmark
type 2 diabetes
GLP-1 agonists
Novo Nordisk
Ozempic